Quantum BioPharma Ltd. - Asset Resilience Ratio
Quantum BioPharma Ltd. (QNTM) has an Asset Resilience Ratio of 38.13% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Quantum BioPharma Ltd. to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2020–2025)
This chart shows how Quantum BioPharma Ltd.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Quantum BioPharma Ltd. total assets.
Liquid Assets Composition Over Time
This chart breaks down Quantum BioPharma Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore QNTM long-term investments to assets to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $5.71 Million | 38.13% |
| Total Liquid Assets | $5.71 Million | 38.13% |
Asset Resilience Insights
- Very High Liquidity: Quantum BioPharma Ltd. maintains exceptional liquid asset reserves at 38.13% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Quantum BioPharma Ltd. Industry Peers by Asset Resilience Ratio
Compare Quantum BioPharma Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Quantum BioPharma Ltd. (2020–2025)
The table below shows the annual Asset Resilience Ratio data for Quantum BioPharma Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 38.30% | $4.27 Million | $11.14 Million | +31.28pp |
| 2024-12-31 | 7.02% | $1.20 Million | $17.12 Million | +2.70pp |
| 2023-12-31 | 4.33% | $756.10K | $17.47 Million | +4.27pp |
| 2022-12-31 | 0.06% | $23.19K | $38.41 Million | -0.19pp |
| 2021-12-31 | 0.25% | $158.04K | $62.96 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $41.97 Million | -- |
About Quantum BioPharma Ltd.
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company. The company operates through two segments, Biopharmaceutical Innovation and Strategic Investments. It researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in d… Read more